Harmony Biosciences Holdings Inc (HRMY)
29.02
-0.29
(-0.99%)
USD |
NASDAQ |
May 17, 16:00
29.02
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Enterprise Value: 1.466B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.466B |
| May 16, 2024 | 1.482B |
| May 15, 2024 | 1.504B |
| May 14, 2024 | 1.513B |
| May 13, 2024 | 1.534B |
| May 10, 2024 | 1.529B |
| May 09, 2024 | 1.594B |
| May 08, 2024 | 1.618B |
| May 07, 2024 | 1.599B |
| May 06, 2024 | 1.573B |
| May 03, 2024 | 1.611B |
| May 02, 2024 | 1.617B |
| May 01, 2024 | 1.537B |
| April 30, 2024 | 1.573B |
| April 29, 2024 | 1.479B |
| April 26, 2024 | 1.483B |
| April 25, 2024 | 1.461B |
| April 24, 2024 | 1.478B |
| April 23, 2024 | 1.456B |
| April 22, 2024 | 1.484B |
| April 19, 2024 | 1.487B |
| April 18, 2024 | 1.466B |
| April 17, 2024 | 1.475B |
| April 16, 2024 | 1.509B |
| April 15, 2024 | 1.494B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.493B |
| April 11, 2024 | 1.593B |
| April 10, 2024 | 1.486B |
| April 09, 2024 | 1.570B |
| April 08, 2024 | 1.512B |
| April 05, 2024 | 1.558B |
| April 04, 2024 | 1.591B |
| April 03, 2024 | 1.618B |
| April 02, 2024 | 1.675B |
| April 01, 2024 | 1.692B |
| March 31, 2024 | 1.725B |
| March 28, 2024 | 1.746B |
| March 27, 2024 | 1.743B |
| March 26, 2024 | 1.658B |
| March 25, 2024 | 1.691B |
| March 22, 2024 | 1.731B |
| March 21, 2024 | 1.745B |
| March 20, 2024 | 1.750B |
| March 19, 2024 | 1.675B |
| March 18, 2024 | 1.633B |
| March 15, 2024 | 1.656B |
| March 14, 2024 | 1.620B |
| March 13, 2024 | 1.539B |
| March 12, 2024 | 1.567B |
| March 11, 2024 | 1.587B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
951.04M
Minimum
Oct 27 2023
3.497B
Maximum
Dec 05 2022
2.176B
Average
2.079B
Median
Feb 24 2021
Enterprise Value Benchmarks
| Amylyx Pharmaceuticals Inc | -248.84M |
| Exelixis Inc | 5.128B |
| Insmed Inc | 4.248B |
| Ultragenyx Pharmaceutical Inc | 3.069B |
| Immunic Inc | 14.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 38.33M |
| Revenue (Quarterly) | 154.62M |
| Total Expenses (Quarterly) | 102.58M |
| EPS Diluted (Quarterly) | 0.67 |
| Gross Profit Margin (Quarterly) | 82.22% |
| Profit Margin (Quarterly) | 24.79% |
| Earnings Yield | 7.96% |
| Operating Earnings Yield | 11.80% |
| Normalized Earnings Yield | 8.369 |